Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
MRVI Maravai Lifesciences Holdings Inc
- Stocks
- Healthcare
- NASDAQ: MRVI
Price (delayed)
$2.21
Market cap
$562.8M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.14
Enterprise value
$604.4M
Maravai LifeSciences enables the development of drug therapies, diagnostics and novel vaccines and supports research on human diseases through its portfolio of market-leading companies and proprietary technologies. Maravai companies are
Highlights
The company's debt fell by 41% YoY
Maravai Lifesciences Holdings's quick ratio has shrunk by 51% YoY and by 22% QoQ
The company's equity fell by 27% YoY and by 8% QoQ
Key stats
What are the main financial stats of MRVI
Market
Valuations
Earnings
Shares outstanding
254.66M
Market cap
$562.8M
Enterprise value
$604.4M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.87
Price to sales (P/S)
1.31
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.5
Revenue
$241.86M
Gross profit
$90.19M
Operating income
-$267.92M
Net income
-$162.71M
EBIT
-$121.07M
EBITDA
-$63.05M
Free cash flow
-$16.23M
Per share
Balance sheet
Liquidity
EPS
-$1.14
EPS diluted
-$1.14
Free cash flow per share
-$0.11
Book value per share
$1.18
Revenue per share
$1.69
TBVPS
$4.19
Total assets
$959.75M
Total liabilities
$429.48M
Debt
$326.65M
Equity
$300.61M
Working capital
$313.12M
Debt to equity
1.09
Current ratio
5.96
Quick ratio
4.96
Net debt/EBITDA
-0.66
Margins
Efficiency
Dividend
EBITDA margin
-26.1%
Gross margin
37.3%
Net margin
-67.3%
Operating margin
-110.8%
Return on assets
-13.9%
Return on equity
-46.2%
Return on invested capital
-17.1%
Return on capital employed
-13.5%
Return on sales
-50.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MRVI stock price
How has the Maravai Lifesciences Holdings stock price performed over time
Intraday
-0.45%
1 week
0%
1 month
6.76%
1 year
-74.6%
YTD
-59.45%
QTD
0%
Financial performance
How have Maravai Lifesciences Holdings's revenue and profit performed over time
Revenue
$241.86M
Gross profit
$90.19M
Operating income
-$267.92M
Net income
-$162.71M
Gross margin
37.3%
Net margin
-67.3%
The company's net margin fell by 41% YoY and by 20% QoQ
Maravai Lifesciences Holdings's gross profit has decreased by 25% YoY and by 17% QoQ
MRVI's net income is down by 24% year-on-year and by 12% since the previous quarter
The operating margin has decreased by 21% from the previous quarter
Price vs fundamentals
How does MRVI's price correlate with its fundamentals
Growth
What is Maravai Lifesciences Holdings's growth rate over time
Valuation
What is Maravai Lifesciences Holdings stock price valuation
P/E
N/A
P/B
1.87
P/S
1.31
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.5
Maravai Lifesciences Holdings's EPS has decreased by 15% YoY and by 9% from the previous quarter
MRVI's price to book (P/B) is 92% less than its 5-year quarterly average of 22.0 and 54% less than its last 4 quarters average of 4.1
The company's equity fell by 27% YoY and by 8% QoQ
The price to sales (P/S) is 69% less than the 5-year quarterly average of 4.2 and 56% less than the last 4 quarters average of 3.0
Maravai Lifesciences Holdings's revenue has decreased by 12% YoY and by 7% from the previous quarter
Efficiency
How efficient is Maravai Lifesciences Holdings business performance
The company's return on invested capital has shrunk by 131% YoY and by 34% QoQ
Maravai Lifesciences Holdings's ROS has plunged by 120% YoY and by 31% from the previous quarter
The return on assets has dropped by 99% year-on-year and by 24% since the previous quarter
The return on equity has dropped by 64% year-on-year and by 21% since the previous quarter
Dividends
What is MRVI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MRVI.
Financial health
How did Maravai Lifesciences Holdings financials performed over time
MRVI's total assets is 123% greater than its total liabilities
Maravai Lifesciences Holdings's quick ratio has shrunk by 51% YoY and by 22% QoQ
Maravai Lifesciences Holdings's current ratio has decreased by 47% YoY and by 21% from the previous quarter
The company's debt is 9% higher than its equity
The company's debt fell by 41% YoY
The company's equity fell by 27% YoY and by 8% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.